Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRX NASDAQ:FBLG NASDAQ:JSPR NASDAQ:LGVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$0.60+14.3%$0.40$0.00▼$3.87$7.79M0.833,652 shs300 shsFBLGFibroBiologics$1.03-3.7%$1.40$0.95▼$19.80$5.37M1.13281,165 shs74,873 shsJSPRJasper Therapeutics$0.49+2.4%$0.85$0.43▼$7.19$13.79M3581,430 shs558,087 shsLGVNLongeveron$0.73-8.8%$0.91$0.48▼$1.80$22.74M-0.35421,154 shs306,249 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals+14.29%+4.35%+57.89%+300.00%-71.43%FBLGFibroBiologics-3.74%-11.21%-20.16%-88.16%-93.94%JSPRJasper Therapeutics+2.37%-40.57%-47.96%-64.30%-91.79%LGVNLongeveron-8.75%-5.46%-16.48%+50.95%-38.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$0.60+14.3%$0.40$0.00▼$3.87$7.79M0.833,652 shs300 shsFBLGFibroBiologics$1.03-3.7%$1.40$0.95▼$19.80$5.37M1.13281,165 shs74,873 shsJSPRJasper Therapeutics$0.49+2.4%$0.85$0.43▼$7.19$13.79M3581,430 shs558,087 shsLGVNLongeveron$0.73-8.8%$0.91$0.48▼$1.80$22.74M-0.35421,154 shs306,249 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals+14.29%+4.35%+57.89%+300.00%-71.43%FBLGFibroBiologics-3.74%-11.21%-20.16%-88.16%-93.94%JSPRJasper Therapeutics+2.37%-40.57%-47.96%-64.30%-91.79%LGVNLongeveron-8.75%-5.46%-16.48%+50.95%-38.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/AFBLGFibroBiologics 2.00Hold$74.007,084.47% UpsideJSPRJasper Therapeutics 2.33Hold$13.142,567.52% UpsideLGVNLongeveron 2.25Hold$5.50653.42% UpsideCurrent Analyst Ratings BreakdownLatest FBLG, LGVN, EGRX, and JSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026FBLGFibroBiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/22/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/15/2026JSPRJasper Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetSector Perform$4.00 ➝ $3.005/15/2026JSPRJasper Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/11/2026LGVNLongeveron Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/4/2026FBLGFibroBiologics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/4/2026LGVNLongeveron HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.004/21/2026FBLGFibroBiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026JSPRJasper Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026FBLGFibroBiologics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00 ➝ $8.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.03$1.50 per share0.40N/A∞FBLGFibroBiologicsN/AN/AN/AN/A$1.85 per shareN/AJSPRJasper TherapeuticsN/AN/AN/AN/A$0.15 per shareN/ALGVNLongeveron$1.20M18.95N/AN/A$0.25 per share2.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64M$1.180.51N/AN/AN/AN/AN/A8/11/2026 (Estimated)FBLGFibroBiologics-$18.65M-$6.93N/AN/AN/AN/A-767.07%-195.56%7/30/2026 (Estimated)JSPRJasper Therapeutics-$75.80M-$3.23N/AN/AN/AN/A-613.51%-162.52%8/12/2026 (Estimated)LGVNLongeveron-$22.70M-$1.13N/AN/AN/A-1,844.49%-202.41%-140.67%8/12/2026 (Estimated)Latest FBLG, LGVN, EGRX, and JSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026JSPRJasper Therapeutics-$0.46-$0.38+$0.08-$0.04N/AN/A5/13/2026Q1 2026LGVNLongeveron-$0.19-$0.19N/A-$0.19$0.33 million$0.40 million4/30/2026Q1 2026FBLGFibroBiologics-$1.3340-$1.33+$0.0040-$1.33N/AN/A3/30/2026Q4 2025JSPRJasper Therapeutics-$0.79-$0.3250+$0.4650-$0.32N/AN/A3/17/2026Q4 2025LGVNLongeveron-$0.42-$0.22+$0.20-$0.22$0.11 million$0.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/AFBLGFibroBiologicsN/A1.591.59JSPRJasper TherapeuticsN/A2.262.26LGVNLongeveron0.053.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%FBLGFibroBiologicsN/AJSPRJasper Therapeutics79.85%LGVNLongeveron10.01%Insider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%FBLGFibroBiologics9.30%JSPRJasper Therapeutics4.60%LGVNLongeveron7.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataFBLGFibroBiologics105.21 million4.73 millionN/AJSPRJasper Therapeutics2028.00 million26.71 millionOptionableLGVNLongeveron2031.15 million28.84 millionNot OptionableFBLG, LGVN, EGRX, and JSPR HeadlinesRecent News About These CompaniesLongeveron Announces CFO Transition to Internal SuccessorJune 5 at 5:30 PM | tipranks.comLongeveron to Present at BIO International Convention 2026June 4 at 9:15 AM | globenewswire.comLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key PrioritiesMay 20, 2026 | globenewswire.comLongeveron Earnings Call: Trial Milestones Amid FDA HurdlesMay 14, 2026 | tipranks.comLGVN Set for Success in 2026May 14, 2026 | finance.yahoo.comLongeveron (LGVN) Q1 2026 Earnings TranscriptMay 14, 2026 | fool.comLongeveron Inc. (LGVN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comLongeveron Announces 2026 First Quarter Financial Results and Provides Business UpdateMay 13, 2026 | globenewswire.comMaxim Group downgrades Longeveron (LGVN)May 12, 2026 | msn.comLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart ...May 11, 2026 | markets.businessinsider.comLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)May 11, 2026 | globenewswire.comLGVN stock slips after hours as FDA flags concerns on rare heart defect trial designMay 10, 2026 | msn.comLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart ...May 10, 2026 | markets.businessinsider.comLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)May 8, 2026 | globenewswire.comLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026May 5, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Longeveron (LGVN)April 16, 2026 | theglobeandmail.comLongeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)April 8, 2026 | globenewswire.comLongeveron Receives Extended Nasdaq Compliance Grace PeriodMarch 25, 2026 | tipranks.comLongeveron Cancels Special Meeting, Reschedules Reverse Split VoteMarch 24, 2026 | tipranks.comLongeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call TranscriptMarch 19, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBLG, LGVN, EGRX, and JSPR Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$0.60 +0.08 (+14.29%) As of 06/5/2026 03:22 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.FibroBiologics NASDAQ:FBLG$1.03 -0.04 (-3.74%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.00 -0.03 (-3.01%) As of 06/5/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Jasper Therapeutics NASDAQ:JSPR$0.49 +0.01 (+2.37%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.50 +0.00 (+0.67%) As of 06/5/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Longeveron NASDAQ:LGVN$0.73 -0.07 (-8.75%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.73 +0.00 (+0.41%) As of 06/5/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
